Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769651 | 0.73 | KHK (0.48) | KHKTRPV4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL14691380 | 0.72 | VCAM1 (0.41) | TRPV4CYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL23088100 | 0.72 | CYP2A6 (0.38) | TRPV4CYP2D6NOS2ALDH1A1 | |
| SCHEMBL31504178 | 0.72 | TRPV4 (0.56) | KHKTRPV4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1880028 | 0.72 | TRPV4 (0.56) | KHKTRPV4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30110369 | 0.72 | ALDH1A1 (0.50) | KHKTRPV4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL7575800 | 0.72 | ALDH1A1 (0.50) | KHKTRPV4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL13587714 | 0.69 | SLC6A4 (0.34) | SLC6A4CYP11B2 | |
| SCHEMBL25257701 | 0.68 | CYP11B2 (0.47) | ALDH1A1CYP11B2 | |
| SCHEMBL30510146 | 0.68 | CYP11B2 (0.47) | ALDH1A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024008176-A1 | HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5•MTA AND USE THEREOF | 西藏海思科制药有限公司 | 2024-01-11 | — | — | WO | disclosed |